Researchers in the Department of Neurosurgery, the Maxine Dunitz Neurosurgical Institute and the Department of Pathology and Laboratory Medicine at Cedars-Sinai contributed to a major, multicenter study providing a better understanding of genes involved in development of glioblastoma multiforme (GBM), the most common and deadly brain tumor affecting adults.
In an expansion of a study published in 2008, experts with The Cancer Genome Atlas Research Network examined more than 590 GBM samples – nearly 400 more than were included in 2008 – to identify several new significantly mutated genes.
Cedars-Sinai researchers submitted tumor samples, blood samples, full treatment evaluations and outcome data from about 100 patients, according to Julia Ljubimova, MD, PhD, director of drug delivery and nanomedicine, who said the study included data from 543 patients with GBM. Findings were published in the Oct. 10 issue of the journal Cell; The Cancer Genome Atlas described the study in an Oct. 28 news release.
Ljubimova, who also is a professor of neurosurgery and biomedical sciences, and Keith Black, MD, chair and professor of the Department of Neurosurgery, director of the Maxine Dunitz Neurosurgical Institute and director of the Johnnie L. Cochran, Jr. Brain Tumor Center, were listed among authors from about 40 collaborating centers.
The Cancer Genome Atlas is jointly funded and managed by the National Cancer Institute and the National Human Genome Research Institute, both part of the National Institutes of Health.
Photo: Image of a human glioblastoma multiforme cell line, the most common and deadly brain tumor affecting adults, growing in a mouse model.